Search by TEST name

 New Search
 Field Name  Data Description
Test Name  Nortriptyline Level.
Code  Nortriptyline Level.
CPT Code  80335
Last Modified  4/26/2018 2:32:00 PM
Test Name  Nortriptyl.
Synonyms  Routin, Pamelo, Aventy, Tricyc, Nortri, TDM, Aventyl, Pamelor
Patient Preparation  
Spec. Requirements  Blood
Tube  Red, Lavender-top (EDTA) or Green-top (Heparin)
Collection Volume  Red 4.0 mL, Lavender-top (EDTA) 2.0 mL or Green-top (Heparin) 4.0 mL
Storage  Ambient, Refrigerated or Frozen 14 Days
Routine TAT  
STAT TAT  N/A
Days Test Performed  
Performed by BHS  None
See Availability  
Reference Lab  LabCorp of America
Reference Lab Code  007393 Nortiptyline (Aventyl), Serum
Clinical Use  Nortriptyline, the N-demethylated metabolite of amitriptyline, is as effective as imipramine in the treatment of depressive episodes of major depression and bipolar disorder. It may also be useful in dysthymic disorder and atypical depression. Plasma concentrations <50 ng/mL are thought to be ineffective and those >150-175 ng/mL are often associated with a suboptimal response in patients with major depression; therefore, excessive dosage may diminish responsiveness. In addition, active metabolites of nortriptyline may accumulate in elderly patients, and toxic side effects may develop despite plasma nortriptyline concentrations <150 ng/mL; however, in one study, the pharmacokinetic parameters of nortriptyline in frail elderly patients were similar to those in younger individuals. Nortriptyline may be less likely than other tricyclic agents to produce orthostatic hypotension, particularly in the elderly. It also may be relatively safer than other tricyclic antidepressants in cardiac patients, including those who have received a transplant. Nortriptyline, a tricyclic antidepressant, is a derivative and metabolite of amitriptyline and is used to treat endogenous depression. The half-life of nortriptyline is 20 to 80 hours. Nortriptyline may be associated with cholestasis and cholestatic jaundice. Hematological consequences include agranulocytosis, purpura, and thrombocytopenia. Other side effects include a host of GI, endocrinologic, allergic, anticholinergic, cardiovascular, and neurologic disorders. All the tricyclic antidepressants have significant DRUG INTERACTIONS. Being potent inducers of hepatic drug-metabo-lizing enzymes, particularly CYP3A4, CYP1A2, AND CYP2C9, theantiepileptic drugs, carbamazepine, phenytoin, phenobarbitaland primidone stimulate the oxidative transformation of concurrently prescribed antidepressants. [1] This results indecreased drug levels of the antidepressant. To a lesser extent, co-administration of oxcarbazepine, topiramate, and felbamate can also result in decreased antidepressant levels. OTHER TRICYCLIC ANTIDEPRESSANT DRUG INTERACTIONS: hydrocortisone, methylphenidate, and phenothiazines increasetricyclic levels; tricyclics impair the antihypertensive effectiveness of clonidine and guanethidine; tricyclics and alcohol produce additive sedative effects, tricyclics and antiparkinsonism agents have potent anticholinergic side effects, and tricyclics and MAO inhibitors should not be co-administered because of the potential for antihypertensive and CNS crises. Tricyclics should be avoided in pregnant and lactating women because these drugs have not been established as safe.Geriatric patients are especially prone to postural hypo- tension, urinary retention, and sedation.[2] In general, it has been reported that, "Therapeutic drug monitoring of antidepressants allows us to take into account the influenceof factors such as co-medications, diet, smoking habit, impaired organ function, and compliance. Therapeutic drug monitoring and genotyping are thus complementary, and their combined use contributes to improve pharmacotherapy with antidepressants and other drugs."[3]
Reference Range  Therapeutic: 50−150 ng/mL
Critical Value  Potentially toxic: >500 ng/mL
Component  Nortriptyline
Reference Range  50 - 150 ng/ml
Critical Value  
Testing Sample Type  Serum or Plasma
Min Lab Testing Volume  0.3 mL
Special Handling  DO NOT USE A GEL-BARRIER TUBE. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Lab Notes  Collection: Transfer separated serum or plasma to a plastic transport tube. For therapeutic monitoring, collect specimen immediately prior to next dose. Cause for rejection: Gel-barrier tube
Methodology  LC/MS-MS - Liquid Chromatography/Tandem Mass Spectrometry
Limitations  
 

Top of Page

New Search